利培酮与氯氮平治疗难治性精神分裂症对照研究

A comparative trial on the efficacy of risperidone and clozapine in treatment-resistant schizophrenia

目的 比较利培酮与氯氮平治疗难治性精神分裂症的疗效和副反应。方法 将符合入组条件的病人随机分为2组,分别服用利培酮和氯氮平治疗12周,用PANSS和TESS评定疗效和副反应情况。结果 利培酮组总有效率为62.9％,氯氮平组为60.0％,经统计学处理无显著性差异(P>0.05)。结论 利培酮对难治性精神分裂症的疗效与氯氮平相当,副作用轻,易被病人接受。

Objective To compare the efficacy and side-effect of risperidone with that of clozapine in patients with treatment-resistant schizophrenia. Methods Patients with diagnosis of treatment-resistant schizophrenia were randomly assigned to two groups that were treated with either risperidone or clozapine for 12 weeks. The therapeutic response and side effects were evaluated with the PANSS and TESS. Results The overall therapeutic effect rate of risperidone was 62. 9%. The overall therapeutic effect rate of clozapine was 60.0%. There were no statistical differences in the PANSS total scores and N or G scale scores between the two groups (P>0. 05). Conclusion No significant differences are found in the efficacy between the two groups. Risperidone shows fewer side effects than clozapine and is easily accepted by patients.